182 related articles for article (PubMed ID: 17487349)
1. Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes.
Gordon EM; Chan MT; Geraldino N; Lopez FF; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Hall FL
Int J Oncol; 2007 Jun; 30(6):1297-307. PubMed ID: 17487349
[TBL] [Abstract][Full Text] [Related]
2. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.
Gordon EM; Levy JP; Reed RA; Petchpud WN; Liu L; Wendler CB; Hall FL
Int J Oncol; 2008 Oct; 33(4):665-75. PubMed ID: 18813779
[TBL] [Abstract][Full Text] [Related]
3. Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience.
Gordon EM; Lopez FF; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Bruckner HW; Hall FL
Int J Oncol; 2006 Nov; 29(5):1053-64. PubMed ID: 17016635
[TBL] [Abstract][Full Text] [Related]
4. Rexin-G, a targeted genetic medicine for cancer.
Gordon EM; Hall FL
Expert Opin Biol Ther; 2010 May; 10(5):819-32. PubMed ID: 20384524
[TBL] [Abstract][Full Text] [Related]
5. Technology evaluation: Rexin-G, Epeius Biotechnologies.
Morse M
Curr Opin Mol Ther; 2005 Apr; 7(2):164-9. PubMed ID: 15844625
[TBL] [Abstract][Full Text] [Related]
6. Systemic genetic transfer of p21WAF-1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex.
Liu X; Tian PK; Ju DW; Zhang MH; Yao M; Cao XT; Gu JR
Cancer Gene Ther; 2003 Jul; 10(7):529-39. PubMed ID: 12833133
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct.
Gordon EM; Liu PX; Chen ZH; Liu L; Whitley MD; Gee C; Groshen S; Hinton DR; Beart RW; Hall FL
Cancer Res; 2000 Jul; 60(13):3343-7. PubMed ID: 10910035
[TBL] [Abstract][Full Text] [Related]
8. First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
Gordon EM; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Hall FL
Int J Oncol; 2004 Jan; 24(1):177-85. PubMed ID: 14654955
[TBL] [Abstract][Full Text] [Related]
9. The 'timely' development of Rexin-G: first targeted injectable gene vector (review).
Gordon EM; Hall FL
Int J Oncol; 2009 Aug; 35(2):229-38. PubMed ID: 19578735
[TBL] [Abstract][Full Text] [Related]
10. Local gene therapy of solid tumors with GM-CSF and B7-1 eradicates both treated and distal tumors.
Collins CG; Tangney M; Larkin JO; Casey G; Whelan MC; Cashman J; Murphy J; Soden D; Vejda S; McKenna S; Kiely B; Collins JK; Barrett J; Aarons S; O'Sullivan GC
Cancer Gene Ther; 2006 Dec; 13(12):1061-71. PubMed ID: 16874363
[TBL] [Abstract][Full Text] [Related]
11. Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules.
Nemeckova S; Smahel M; Hainz P; Mackova J; Zurkova K; Gabriel P; Indrova M; Kutinova L
Neoplasma; 2007; 54(4):326-33. PubMed ID: 17822323
[TBL] [Abstract][Full Text] [Related]
12. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
Jinushi M; Hodi FS; Dranoff G
Immunol Rev; 2008 Apr; 222():287-98. PubMed ID: 18364009
[TBL] [Abstract][Full Text] [Related]
13. [Molecular therapy in malignant tumors].
Fey MF
Schweiz Med Wochenschr; 1999 Nov; 129(46):1758-63. PubMed ID: 10603649
[TBL] [Abstract][Full Text] [Related]
14. Sonoporation mediated immunogene therapy of solid tumors.
Casey G; Cashman JP; Morrissey D; Whelan MC; Larkin JO; Soden DM; Tangney M; O'Sullivan GC
Ultrasound Med Biol; 2010 Mar; 36(3):430-40. PubMed ID: 20133039
[TBL] [Abstract][Full Text] [Related]
15. [Effect of Fluorouracil-inducible GM-CSF gene therapy regulated by Egr-1 promoter on chemotherapeutic hematopoietic damage of tumor-bearing mice].
Du N; Pei XT; Xiao WH; Sun JZ; Fu Y; Zhao H; Wang XL
Zhonghua Yi Xue Za Zhi; 2009 May; 89(18):1281-6. PubMed ID: 19595187
[TBL] [Abstract][Full Text] [Related]
16. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
[TBL] [Abstract][Full Text] [Related]
17. [Progress of gene therapy for esophageal cancer in Japan].
Matsubara H; Ochiai T
Gan To Kagaku Ryoho; 2003 Jul; 30(7):944-9. PubMed ID: 12894708
[TBL] [Abstract][Full Text] [Related]
18. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS
J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833
[TBL] [Abstract][Full Text] [Related]
19. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy.
Uchibori R; Okada T; Ito T; Urabe M; Mizukami H; Kume A; Ozawa K
J Gene Med; 2009 May; 11(5):373-81. PubMed ID: 19274675
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]